Anugel
Phase 2- Indications
- Post-surgical pain
Company intelligence / Profile preview
Deep Life Medical
Edinburgh, Scotland, UKdeeplifemedical.com ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
Deep Life Medical develops, produces, and licenses medical devices and plant-based therapeutics. Its flagship gel product Anugel™ has shown efficacy in reducing analgesic use after surgery in a randomized clinical trial. The company is also advancing a plant-derived therapy for sickle cell disease into Phase 3 trials. It is ISO-certified and distributes its products internationally across Europe, Russia/CIS, Turkey, Nigeria, Central America, Australasia, and East Asia.
- Therapeutic areas
- OtherPulmonologyHematology
- Modalities
- DevicePhytopharmacologySmall molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Deep Life Medical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Deep Life Medical.